Pharming Group NV

Pharming Group NV: Human protein replacement therapies, in rare/ultra-rare diseases, plus new small molecule program for APDS. RUCONEST (rhC1INH), the only recombinant enzyme replacement therapy marketed for acute Hereditary Angioedema (HAE) attacks and being developed for large unmet indications. Profitable and cash flow positive – revenue from product sales €138M (1st 9 months 2020) and €169M (full year 2019). Growth (9 mo. YOY) in revenues (+9.2%), operating profit (+20%) and net profit (+6%). Development pipeline includes RUCONEST in new lower volume versions, active buisness development strategy; recent in-license from Novartis of late stage drug Leniolisib for APDS (ultra-rare immunodeficiency condition), rhC1INH for new larger indications including COVID-19, pre-eclampsia, AKI and additional pipeline product from technology platform: recombinant alpha-Glucosidase for Pompe disease.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Marketed
Disease Space
Anti-inflammatory, Autoimmune, Rare Disease
Finance
Profitable, Revenues
Industry
Biotechnology
Investement Strategy
Under the Radar
Listing
Europe, Public
Market Cap
500MM - 1B
Therapeutic Modalities
Recombinant DNA
Website:
Address:
Vondellaan 47
Leiden, Zuid-Holland 2332AA
Netherlands

Company Participants at European Biotech Investor Days 2021

Sijmen de Vries
Pharming Group NV, CEO
Dr. De Vries is responsible for the overall management of the Company. Dr. De Vries has extensive senior level experience in both the pharmaceutical and biotechnology industry. He joined Pharming from Switzerland-based 4-Antibody where he was CEO. Dr. De Vries has also been CEO of Morphochem AG and prior to this he worked at Novartis Pharma and Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc where he held senior business and commercial positions. Dr. De Vries holds an MD degree from the University of Amsterdam and a MBA in General Management from Ashridge Management College (UK)

Upcoming Company Event Participation

Top 10 Holders of Pharming Group NV

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Goldman Sachs Asset Management LP 2.14 13,674,620 17.62 Stakes 4/3/20
Schroder Investment Management Ltd. 1.50 9,582,137 12.35 Stakes 7/21/20
Schroder Investment Management North America, Inc. 1.41 9,005,064 11.60 Stakes 7/21/20
DWS Investments (UK) Ltd. 0.61 3,887,739 5.01 Stakes 4/21/20
Teachers Advisors LLC 0.54 3,390,728 4.37 Funds 12/31/20
Argenta Banque d'Epargne SA 0.51 3,215,250 4.14 Funds 12/30/20
LSV Asset Management 0.50 3,150,200 4.06 Funds 11/30/20
TIAA-CREF Investment Management LLC 0.45 2,804,623 3.61 Funds 12/31/20
Nordea Investment Management AB 0.44 2,745,052 3.54 Funds 12/31/20
RAM Active Investments SA 0.32 2,064,835 2.66 Funds 6/30/20

Top 10 Holders of Pharming Group NV ADR RegS

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
JW Asset Management LLC 2.97 1,895,941 2.44 13F 12/31/20
UBS Group AG (13f Subfiler) 0.00 916 0.00 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.